Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
- Written by PR Newswire
- FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the clinical potential in advanced mesothelioma.
- ISM6331 is a novel, potential best-in-class, pan-TEAD inhibitor engineered via Chemistry42 to restore Hippo pathway balance, and its Phase I first-in-human...
